Page contents Key factsDecisionKey facts Active Substance atorvastatin calciumfenofibrate Therapeutic area Congenital, familial and genetic disorders Decision number P/0162/2024 PIP number EMEA-003563-PIP01-23 Pharmaceutical form(s) Film-coated tablet Condition(s) / indication(s) Treatment of hyperlipidaemia Route(s) of administration Oral use Contact for public enquiries Althera Laboratories LimitedEmail: regulatory.eu@altherainc.comTel.: +353 1 906 0479 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 06/05/2024Share this page